Abraham Sartani - 18 Mar 2026 Form 3 Insider Report for Can-Fite BioPharma Ltd. (CANF)

Role
Director
Signature
/s/ Abraham Sartani
Issuer symbol
CANF
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 08:13:24 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sartani Abraham Director C/O CAN-FITE BIOPHARMA LTD., 26 BEN GURION STREET, RAMAT GAN, ISRAEL /s/ Abraham Sartani 18 Mar 2026 0001331868

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CANF Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 16 $2826.14 Direct F1, F2, F3
holding CANF Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 2,166 $25.21 Direct F1, F4
holding CANF Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 200 $241.47 Direct F1, F2, F5
holding CANF Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 2,166 $26.56 Direct F1, F6
holding CANF Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 16,000 $2.18 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
F2 These options are fully vested and exercisable as of the date hereof.
F3 The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 8778, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
F4 The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 677 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F5 The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
F6 The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F7 The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none of the options are vested, and the remaining 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.